Effects of Sacubitril/Valsartan in treatment of elderly patients with chronic heart failure
Objective:To observe effects of Sacubitril/Valsartan in treatment of elderly patients with chronic heart failure(CHF).Methods:A prospective study was conducted on 168 elderly patients with CHF admitted to this hospital from January 2022 to January 2023.According to the random number table method,they were divided into observation group and control group,84 cases in each group.The control group was treated with conventional anti-heart failure drugs,while the observation group was treated with Sacubitril/Valsartan tablets on the basis of that of the control group.The clinical efficacy,the levels of cardiac function indexes[left atrial volume index(LAVI),left ventricular end-diastolic diameter(LVEDD),left ventricular blood fraction(LVEF)]and disease related indexes[matrix metalloproteinase-9(MMP-9),N-terminal pro-brain natriuretic peptide(NT-proBNP),interleukin-6(IL-6)],exercise tolerance[6-minute walking test distance(6MWD)],and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the observation group was 95.24%(80/84),which was higher than 85.71%(72/84)of the control group,and the difference was statistically significant(P＜0.05).After the treatment,the LVEF levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the levels of LAVI and LVEDD in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P＜0.05).The levels of MMP-9,NT-proBNP and IL-6 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).The 6MWD of the two groups were longer than those before the treatment,that in the observation group was longer than that in the control group,and the difference was statistically significant(P＜0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusions:On the basis of conventional anti-heart failure drug treatment,Sacubitril/Valsartan in the treatment of the elderly CHF patients can improve the total effective rate of treatment and the exercise endurance levels,improve the levels of cardiac function indexes,and reduce the levels of disease related indexes.Moreover,it is superior to simple conventional anti heart failure drug treatment.
NETL
NSTL
万方数据
